1/23/2009

Johnson & Johnson announced that the European Commission approved the use of ustekinumab, a psoriasis treatment, for patients who do not benefit from other anti-inflammatory medicines. In December, the FDA deferred its decision on the drug and asked J&J to submit additional safety data.

Full Story:
Bloomberg

Related Summaries